Adicet Bio (ACET) has released an update to notify the public and investors about an entry into a material definitive agreement.
Adicet Bio, Inc. entered into an agreement with Jefferies LLC and Guggenheim Securities, LLC for an underwritten public offering of over 27 million shares of common stock and pre-funded warrants for additional shares. The shares and pre-funded warrants were offered publicly at $2.40 and $2.3999 respectively, with the underwriters purchasing at a 6% discount. The underwriters also exercised their option to purchase an additional 5.325 million shares. The offering, expected to close on January 25, 2024, is estimated to net the Company approximately $91.8 million, with additional potential proceeds from warrant exercises, subject to ownership limitations and adjustments.
For further insights into ACET stock, check out TipRanks’ Stock Analysis page.
